The number of patients affected by chronic inflammatory bowel diseases (IBD) is steadily increasing worldwide. As highlighted in a DiaSys publication, potential contributing factors include lifestyle characteristics in industrialized countries, particularly diet and hygiene. Under these conditions, laboratory diagnostics plays a crucial role not only in disease detection but also in continuous monitoring of disease progression.
Why bile acids are becoming a critical biomarker
DiaSys emphasizes that the determination of bile acids (BA) in stool samples is gaining increasing importance as both a screening parameter and a tool for monitoring IBD. At the same time, traditional analytical methods have several limitations:
— they are time-consuming and resource-intensive,
— they require significant financial investment,
— they demand a high level of patient compliance.
As noted by DiaSys, an alternative approach is the clinical-chemical determination of total bile acids in stool, which significantly simplifies laboratory workflows and makes the test more accessible for routine clinical practice.
Fifth-generation cycling method: a logical step forward
The publication highlights that the fifth-generation enzymatic cycling method has already been well validated for the determination of bile acids in serum samples. Extending this approach to stool analysis represents a logical advancement of the methodology and offers multiple advantages for laboratories. However, as the authors point out, the potential of this approach has not yet been fully utilized.
Clinical validation data: what the comparison revealed
In an article published in Clinical Chemistry and Laboratory Medicine, a comparative evaluation of the DiaSys Total bile acids 21 FS assay was performed against alternative methods.
The study results demonstrated that:
— there was a strong correlation between the methods for total bile acids,
— the DiaSys assay showed more accurate recovery of individual bile acids,
— a lower dispersion of results was observed, which is critically important for the correct interpretation of pathological samples.
As emphasized by the authors, this characteristic provides higher diagnostic accuracy when working with patients affected by IBD.
As the official distributor of DiaSys in Ukraine, we note that Total bile acids 21 FS represents a promising solution for laboratories seeking to implement modern, high-throughput, and clinically validated diagnostic methods. The assay integrates seamlessly into automated clinical chemistry analyzers and meets the demands of routine laboratory practice.
DiaSys is an international manufacturer of diagnostic solutions for clinical laboratory medicine, headquartered in Germany. The company specializes in the development and production of high-quality reagents and test systems for clinical chemistry, immunochemistry, and specialized diagnostics.
DiaSys is recognized for its scientifically grounded approach to innovation: all methods undergo thorough clinical validation and are designed to ensure accuracy, reproducibility, and result stability. DiaSys solutions are compatible with automated analyzers and are widely used in routine laboratory practice worldwide.
The company’s products are applied in the diagnosis and monitoring of a broad range of conditions, from metabolic and gastroenterological disorders to complex chronic diseases.
DiaSys collaborates with laboratories, research centers, and clinics in more than 100 countries, making modern laboratory diagnostics accessible, efficient, and clinically relevant.
Primary source
For a more detailed insight into the study results, we recommend referring to the original publication.
